$344 Million is the total value of Sands Capital Ventures, LLC's 18 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 5.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DICE THERAPEUTICS, INC. | $63,861,000 | +30.7% | 3,148,970 | 0.0% | 18.56% | +38.3% | ||
| PATH | UIPATH INC | $48,067,000 | -30.7% | 3,811,779 | 0.0% | 13.97% | -26.6% | |
| NU HOLDINGS LTD. | $40,202,000 | +17.6% | 9,136,835 | 0.0% | 11.68% | +24.5% | ||
| SNOW | SNOWFLAKE INC | $36,477,000 | +22.2% | 214,621 | 0.0% | 10.60% | +29.4% | |
| ABOS | ACUMEN PHARMACEUTICALS, INC | $34,273,000 | +113.4% | 3,417,075 | 0.0% | 9.96% | +125.9% | |
| SAMSARA, INC. | $32,737,000 | +8.1% | 2,712,256 | 0.0% | 9.52% | +14.4% | ||
| DASH | DOORDASH INC | $29,742,000 | -22.9% | 601,454 | 0.0% | 8.64% | -18.4% | |
| TXG | 10X Genomics, Inc. | $13,721,000 | -37.1% | 481,770 | 0.0% | 3.99% | -33.4% | |
| KRTX | Sell | KARUNA THERAPEUTICS, INC. | $13,247,000 | -39.4% | 58,895 | -65.9% | 3.85% | -35.9% |
| OLK | OLINK HOLDING AB | $8,565,000 | -20.1% | 705,514 | 0.0% | 2.49% | -15.5% | |
| MASS | 908 DEVICES INC | $5,370,000 | -20.1% | 326,427 | 0.0% | 1.56% | -15.4% | |
| TARS | TARSUS PHARMACEUTICALS INC | $4,451,000 | +17.3% | 260,000 | 0.0% | 1.29% | +24.2% | |
| RGEN | REPLIGEN CORP. | $4,218,000 | +15.2% | 22,544 | 0.0% | 1.23% | +22.0% | |
| SAMSARA, INC. | $3,935,000 | +8.1% | 326,000 | 0.0% | 1.14% | +14.4% | ||
| CANDEL THERAPEUTICS, INC | $2,549,000 | -3.1% | 811,737 | 0.0% | 0.74% | +2.6% | ||
| TSHA | TAYSHA GENE THERAPIES INC | $1,399,000 | -48.1% | 724,873 | 0.0% | 0.41% | -45.1% | |
| SPRB | SPRUCE BIOSCIENCES INC | $1,078,000 | -21.3% | 787,007 | 0.0% | 0.31% | -16.8% | |
| ABSCI CORP. | $181,000 | -5.7% | 57,804 | 0.0% | 0.05% | 0.0% | ||
| Exit | CINCOR PHARMA, INC. | $0 | – | -950,000 | -100.0% | -4.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UIPATH INC | 9 | Q3 2023 | 30.2% |
| DOORDASH INC | 9 | Q3 2023 | 19.6% |
| SNOWFLAKE INC | 9 | Q3 2023 | 14.4% |
| ACUMEN PHARMACEUTICALS, INC | 9 | Q3 2023 | 10.0% |
| 908 DEVICES INC | 9 | Q3 2023 | 1.8% |
| TARSUS PHARMACEUTICALS INC | 9 | Q3 2023 | 1.4% |
| TAYSHA GENE THERAPIES INC | 9 | Q3 2023 | 2.0% |
| CANDEL THERAPEUTICS, INC | 9 | Q3 2023 | 1.3% |
| SPRUCE BIOSCIENCES INC | 9 | Q3 2023 | 0.7% |
| ABSCI CORPORATION | 9 | Q3 2023 | 0.1% |
View Sands Capital Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-15 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-09 |
View Sands Capital Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.